Teva Chief Medical Officer and Global R&D Head Eric Hughes Departs
Teva Pharmaceutical Industries announces the immediate departure of R&D head and Chief Medical Officer Dr. Eric Hughes, who is leaving to pursue an external career opportunity.

Teva Pharmaceutical Industries announced the immediate departure of Dr. Eric Hughes, its executive vice president, global R&D head, and chief medical officer, just one week after he presented the company's proprietary drug pipeline to investors and analysts at an R&D day in New York. Hughes is leaving to accept an external career opportunity, though he will remain with the pharmaceutical giant for several months to assist with the transition.
Teva confirmed that Dr. David Gardiner, the head of branded pharmaceuticals and clinical development, will step in as interim R&D head while the company initiates a global search for a permanent successor. Executives emphasized that Hughes's departure does not alter the company's long-term strategy, and Teva maintains its projected revenue target of $6 billion to $7 billion from branded medications by 2030.
Leadership Legacy and Background
Hughes joined Teva in August 2022 under former CEO Kare Schultz, managing a workforce of 4,100 employees and overseeing discovery, development, medical affairs, and drug safety across generic, biosimilar, and proprietary portfolios. Prior to joining Teva, he held senior leadership positions at Vertex Pharmaceuticals and Novartis, and holds both MD and PhD degrees from Yale University School of Medicine.
Teva President and CEO Richard Francis acknowledged Hughes's contributions during his tenure.
"Eric made a significant contribution to Teva and to the transformation of our R&D organization. He helped build the pipeline, capabilities, and organization we showcased at our R&D day last week, leaving Teva in a strong position for its next chapter."
Reflecting on his departure, Dr. Hughes expressed pride in the achievements of the research teams under his command.
"I am immensely proud of what our R&D organization has achieved in establishing Teva as a truly innovative biopharma company, as well as the strong team we have built. The progress we presented at R&D day reflects the strength and depth of the organization and the exceptional science we have developed together."





